Therapeutic Indications

Almotriptan is indicated for:

Migraine attacks

Irrespective of gender only Adults (18 years old or older)

Almotriptan is indicated for the acute treatment of the headache phase of migraine attacks with or without aura.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 12.5-25 mg

Contraindications

Active ingredient Almotriptan is contraindicated in the following cases:

Severe hepatic disease

No gender/age discrimination

Treatment with almotriptan is contraindicated in patients with severe hepatic disease.

Ergotamine, ergotamine derivatives, 5-HT1B/1D agonists

No gender/age discrimination

Concomitant administration of almotriptan with ergotamine, ergotamine derivatives (including methysergide) and other 5-HT1B/1D agonists is contraindicated.

Ischaemic heart disease, hypertension

No gender/age discrimination

Almotriptan should not be used in patients with a history, symptoms or signs of ischaemic heart disease (myocardial infarction, angina pectoris, documented silent ischaemia, Prinzmetal’s angina) or severe hypertension and uncontrolled mild or moderate hypertension.

Lactation

No gender/age discrimination

There are no data regarding excretion of almotriptan in human milk. Studies in rats have shown that almotriptan and/or its metabolites are excreted in milk.

Caution should therefore be exercised when prescribing during lactation. Infant exposure may be minimised by avoiding breast feeding for 24 hours after treatment.

Cerebrovascular accident (CVA) or transient ischaemic attack (TIA), peripheral vascular disease

No gender/age discrimination

Almotriptan should not be used in patients with a previous cerebrovascular accident (CVA) or transient ischaemic attack (TIA). Peripheral vascular disease.